Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared

SG&A Spending: Blueprint vs. Bausch Health

__timestampBausch Health Companies Inc.Blueprint Medicines Corporation
Wednesday, January 1, 201420263000007890000
Thursday, January 1, 2015268270000014456000
Friday, January 1, 2016281000000019218000
Sunday, January 1, 2017258200000027986000
Monday, January 1, 2018247300000047928000
Tuesday, January 1, 2019255400000096388000
Wednesday, January 1, 20202367000000157743000
Friday, January 1, 20212624000000195293000
Saturday, January 1, 20222625000000237374000
Sunday, January 1, 20232917000000295141000
Monday, January 1, 2024359272000
Loading chart...

Unlocking the unknown

SG&A Spending Patterns: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Bausch Health Companies Inc. over the past decade.

A Decade of Financial Strategy

From 2014 to 2023, Bausch Health consistently allocated a significant portion of its budget to SG&A, with expenses peaking at approximately $2.9 billion in 2023. This represents a steady increase of about 44% from 2014. In contrast, Blueprint Medicines, a smaller player, exhibited a more aggressive growth in SG&A spending, skyrocketing from $7.9 million in 2014 to nearly $295 million in 2023, marking an exponential increase of over 3,600%.

Strategic Implications

These spending patterns reflect distinct strategic priorities: Bausch Health's focus on maintaining market presence and Blueprint's investment in rapid expansion and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025